178 related articles for article (PubMed ID: 18721895)
1. Challenges for drug studies in children: CYP3A phenotyping as example.
de Wildt SN; Ito S; Koren G
Drug Discov Today; 2009 Jan; 14(1-2):6-15. PubMed ID: 18721895
[TBL] [Abstract][Full Text] [Related]
2. In vitro ADME phenotyping in drug discovery: current challenges and future solutions.
Williams JA; Bauman J; Cai H; Conlon K; Hansel S; Hurst S; Sadagopan N; Tugnait M; Zhang L; Sahi J
Curr Opin Drug Discov Devel; 2005 Jan; 8(1):78-88. PubMed ID: 15679175
[TBL] [Abstract][Full Text] [Related]
3. Theoretical pharmacokinetic drug alterations in pediatric celiac disease.
Tran TH; Smith C; Mangione RA
Expert Opin Drug Metab Toxicol; 2015; 11(10):1539-50. PubMed ID: 26155875
[TBL] [Abstract][Full Text] [Related]
4. CYP3A activity: towards dose adaptation to the individual.
Hohmann N; Haefeli WE; Mikus G
Expert Opin Drug Metab Toxicol; 2016 May; 12(5):479-97. PubMed ID: 26950050
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 3A: genetic polymorphisms and inter-ethnic differences.
Krishna DR; Shekar MS
Methods Find Exp Clin Pharmacol; 2005 Oct; 27(8):559-67. PubMed ID: 16273136
[TBL] [Abstract][Full Text] [Related]
6. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs.
Greenblatt DJ; von Moltke LL
J Clin Pharmacol; 2008 Nov; 48(11):1350-5. PubMed ID: 18757784
[TBL] [Abstract][Full Text] [Related]
7. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found.
Benet LZ
Mol Interv; 2005 Apr; 5(2):79-83. PubMed ID: 15821156
[TBL] [Abstract][Full Text] [Related]
8. Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.
Ince I; Knibbe CA; Danhof M; de Wildt SN
Clin Pharmacokinet; 2013 May; 52(5):333-45. PubMed ID: 23463352
[TBL] [Abstract][Full Text] [Related]
9. Fluorine magnetic resonance in vivo: a powerful tool in the study of drug distribution and metabolism.
Reid DG; Murphy PS
Drug Discov Today; 2008 Jun; 13(11-12):473-80. PubMed ID: 18549972
[TBL] [Abstract][Full Text] [Related]
10. Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages.
Strougo A; Yassen A; Monnereau C; Danhof M; Freijer J
J Clin Pharmacol; 2014 Sep; 54(9):1006-15. PubMed ID: 24676942
[TBL] [Abstract][Full Text] [Related]
11. Developmental pharmacokinetics.
Anderson GD
Semin Pediatr Neurol; 2010 Dec; 17(4):208-13. PubMed ID: 21183126
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of models for predicting drug-drug interactions due to induction.
Fahmi OA; Ripp SL
Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1399-416. PubMed ID: 20955108
[TBL] [Abstract][Full Text] [Related]
13. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics.
Brocks DR
Biopharm Drug Dispos; 2006 Nov; 27(8):387-406. PubMed ID: 16944450
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and pharmacokinetics in children and the elderly.
Pelkonen O
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):147-8. PubMed ID: 17428146
[TBL] [Abstract][Full Text] [Related]
15. Developmental pharmacogenomics.
Neville KA; Becker ML; Goldman JL; Kearns GL
Paediatr Anaesth; 2011 Mar; 21(3):255-65. PubMed ID: 21320234
[TBL] [Abstract][Full Text] [Related]
16. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
Wang J
Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
[TBL] [Abstract][Full Text] [Related]
17. The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
Perera MA
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):17-28. PubMed ID: 19968573
[TBL] [Abstract][Full Text] [Related]
18. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions.
Zhang L; Zhang Y; Huang SM
Mol Pharm; 2009; 6(6):1766-74. PubMed ID: 19839641
[TBL] [Abstract][Full Text] [Related]
19. Developmental pharmacokinetics.
van den Anker JN; Schwab M; Kearns GL
Handb Exp Pharmacol; 2011; 205():51-75. PubMed ID: 21882105
[TBL] [Abstract][Full Text] [Related]
20. Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem.
Croyle MA
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1189-211. PubMed ID: 19732028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
